Latest Breaking News On - Primary biliary cholangitis - Page 6 : comparemela.com

GENFIT: Publication of the 2024 Extra-Financial Performance

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical.

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Ursodeoxycholic Acid Market size is set to grow by USD 358.41 million from 2023-2027, rise in number of liver transplants boost the market, Technavio

/PRNewswire/ The global ursodeoxycholic acid market size is estimated to grow by USD 358.41 million from 2023-2027, according to Technavio. The market is.

Fenofibrates in the Treatment of Primary Biliary Cholangitis

New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.

Seladelpar improves symptoms of primary biliary cholangitis

1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic acid, seladelpar was superior to placebo in achieving biochemical response and symptomatic management. 2. Seladelpar had an acceptable safety profile, with similar rates of adverse events to a placebo. Evidence Rating Level: 1 (Excellent) Study